2020 EACR Liquid Biopsies Sponsored Symposia NeXT Liquid Biopsy, A High Performance, Exome-Wide Liquid Biopsy Assay to Study Tumor Dynamics Erin Newburn, PhD Associate Director, Field Applications Scientist Dan Norton, MBA Sr. Product Manager NeXT Liquid Biopsy™, a first-of-its-kind, high-performance exome-wide [...]
2020 Breast Cancer Summit Presentation Enabling multidimensional tumor immunogenomics for advancing biomarker discovery Christelle Johnson, PhD Senior Field Application Scientist Enabling multidimensional tumor immunogenomics for advancing biomarker discovery Insight into the complex and dynamic interactions between the tumor and immune cells of the microenvironment is essential for cancer immunotherapy translational studies Purpose built [...]
2020 EACR Virtual Congress: Industry Symposium Enabling Composite Biomarker Discovery for Precision Cancer Therapy with an Enhanced Exome and Transcriptome Platform Erin Newburn, MS, PhD Director, Field Application Scientist Enabling Composite Biomarker Discovery for Precision Cancer Therapy with an Enhanced Exome and Transcriptome Platform In this presentation, we’ll provide an overview of the [...]
Biomarker Challenge #2: Analysis of Complex Data More accurate, predictive biomarker analysis may assist in the selection of effective combinatorial immunotherapy treatments for patients. Additionally, the complexity of both the tumor and tumor microenvironment suggests a comprehensive approach is needed for robust characterization of the cancer ecosystem. The ImmunoID NeXT™ platform investigates key aspects [...]
Challenge #1: Comprehensive Biology from a Limited & Difficult Sample More accurate, predictive biomarker analysis may assist in the selection of effective combinatorial immunotherapy treatments for patients. Additionally, the complexity of both the tumor and tumor microenvironment suggests a comprehensive approach is needed for robust characterization of the cancer ecosystem. The ImmunoID NeXTTM [...]
Xtalks Webinar Neoantigens for Personalized Cancer Vaccines-Comprehensive Identification and Effective Selection Developing effective personalized cancer vaccines depends on comprehensively detecting all neoantigens in a tumor sample and then selecting the neoantigens that are most likely to be effective in an individual patient. This process, especially under the timeline demands of clinical trials or [...]
ACE ImmunoID for Biomarker Discovery Maximize your data for translational research. ACE ImmunoID integrates exome and transcriptome data to provide insights into: Mechanisms of immune escape The tumor microenvironment, and Tumor-specific neoantigens
Xtalks webinar: Overcoming the Challenges of Immuno-Oncology Biomarker Discovery From Sample to Analytics Only 20% of patients respond to cancer immunotherapies and determining which patients will respond to which treatment options relies on the identification of predictive biomarkers. Immuno-oncology biomarkers such as tumor mutational burden (TMB) or PD-L1 expression are promising, but have [...]
This online seminar will outline a target enrichment technology to improve next generation sequencing assays for cancer research.
Augmented Exome Sequencing Provides Improved Coverage in Medically Interpretable Genes.